Results 21 to 30 of about 571,490 (260)
Applied Sciences, 2021 Gene therapy aims to silence an oncogene through RNA interference, or replace an abnormal tumour suppressor via gene augmentation. In this study, we intended RNA interference for PRKCA oncogene and gene augmentation for PTEN tumour suppressor with a view
Nabilah Ibnat +2 more
doaj +1 more source
Scandinavian Journal of Gastroenterology, 1985 The central problem in cancer therapy is the poor selectivity of current systemic agents against the common solid tumours. The demonstration that unique segments of DNA, constant in location and conserved in evolution are involved in growth control opens new avenues for basic and clinical research.
+8 more sources
Protein palmitoylation in cancer: molecular functions and therapeutic potential
Molecular Oncology, 2023 Protein S‐palmitoylation (hereinafter referred to as protein palmitoylation) is a reversible lipid posttranslational modification catalyzed by the zinc finger DHHC‐type containing (ZDHHC) protein family.
Binhui Zhou +3 more
doaj +1 more source
Targeting mTOR for cancer therapy
Journal of Hematology & Oncology, 2019 Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua +5 more
doaj +1 more source
Oncogenes and anti-oncogenes in tumorigenesis [PDF]
Reproduction Nutrition Développement, 1990 Recent advances have led to the identification of cellular genes which are involved in the initiation and progression of tumorigenesis. The proto-oncogenes, which normally participate in the regulation of cell proliferation and differentiation, can become oncogenes through alterations in the regulation of their expression and/or their coding sequences.
openaire +3 more sources
Cancer Research, 2008 Abstract Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called “oncogene addiction,” provides a rationale for molecular targeted therapy.
I Bernard, Weinstein, Andrew, Joe
openaire +2 more sources
Nature CommunicationsMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to treat KRAS ...
Panayiotis Anastasiou +15 more
doaj +1 more source
Structural basis for the assembly of the Ragulator-Rag GTPase complex
Nature Communications, 2017 mTORC1 activity is controlled through Rag GTPases, which are anchored to the lysosome through the Ragulator. Here, the authors give molecular insights into Ragulator-Rag GTPase assembly and present the crystal structures of the Ragulator alone and in ...
Ryo Yonehara +12 more
doaj +1 more source
Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation
FEBS Letters, EarlyView.Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe +3 more
wiley +1 more source
The Role of P4HA1 in Multiple Cancer Types and its Potential as a Target in Renal Cell Carcinoma
Frontiers in Genetics, 2022 Background: Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) provides the majority of the catalytic site of the active P4H enzyme. Emerging evidence has revealed that P4HA1 participates in the initiation and development of several malignant tumors.
Yang Li +11 more
doaj +1 more source